10-Q 1 bio-20240331.htm 10-Q bio-20240331
000001220812/312024Q1false0.1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Rate00000122082024-01-012024-03-310000012208us-gaap:CommonClassAMember2024-01-012024-03-310000012208us-gaap:CommonClassBMember2024-01-012024-03-310000012208us-gaap:CommonClassAMember2024-05-030000012208us-gaap:CommonClassBMember2024-05-0300000122082024-03-3100000122082023-12-310000012208us-gaap:CommonClassAMember2024-03-310000012208us-gaap:CommonClassAMember2023-12-310000012208us-gaap:CommonClassBMember2024-03-310000012208us-gaap:CommonClassBMember2023-12-310000012208us-gaap:TreasuryStockCommonMember2024-03-310000012208us-gaap:TreasuryStockCommonMember2023-12-3100000122082023-01-012023-03-3100000122082022-12-3100000122082023-03-310000012208us-gaap:CommonStockMember2023-12-310000012208us-gaap:AdditionalPaidInCapitalMember2023-12-310000012208us-gaap:TreasuryStockCommonMember2023-12-310000012208us-gaap:RetainedEarningsMember2023-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000012208us-gaap:CommonStockMember2024-01-012024-03-310000012208us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000012208us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000012208us-gaap:RetainedEarningsMember2024-01-012024-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000012208us-gaap:CommonStockMember2024-03-310000012208us-gaap:AdditionalPaidInCapitalMember2024-03-310000012208us-gaap:TreasuryStockCommonMember2024-03-310000012208us-gaap:RetainedEarningsMember2024-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000012208us-gaap:CommonStockMember2022-12-310000012208us-gaap:AdditionalPaidInCapitalMember2022-12-310000012208us-gaap:TreasuryStockCommonMember2022-12-310000012208us-gaap:RetainedEarningsMember2022-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000012208us-gaap:CommonStockMember2023-01-012023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000012208us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000012208us-gaap:RetainedEarningsMember2023-01-012023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000012208us-gaap:CommonStockMember2023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-03-310000012208us-gaap:TreasuryStockCommonMember2023-03-310000012208us-gaap:RetainedEarningsMember2023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000012208country:US2024-01-012024-03-310000012208country:US2023-01-012023-03-310000012208srt:EuropeMember2024-01-012024-03-310000012208srt:EuropeMember2023-01-012023-03-310000012208srt:AsiaPacificMember2024-01-012024-03-310000012208srt:AsiaPacificMember2023-01-012023-03-310000012208srt:AmericasMember2024-01-012024-03-310000012208srt:AmericasMember2023-01-012023-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-03-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2024-03-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-03-310000012208bio:OrdinaryVotingSharesMember2024-03-310000012208bio:PreferenceSharesMember2024-03-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-03-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2024-03-310000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2024-01-012024-03-310000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2024-03-310000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2024-01-012024-03-310000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2024-03-310000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2023-12-310000012208bio:OtherLongTermDebtMemberbio:OtherLongTermDebtMember2024-03-310000012208bio:OtherLongTermDebtMemberbio:OtherLongTermDebtMember2023-12-310000012208bio:LifeScienceMember2023-12-310000012208bio:ClinicalDiagnosticsMember2023-12-310000012208bio:LifeScienceMember2024-01-012024-03-310000012208bio:ClinicalDiagnosticsMember2024-01-012024-03-310000012208bio:LifeScienceMember2024-03-310000012208bio:ClinicalDiagnosticsMember2024-03-310000012208us-gaap:CustomerRelationshipsMember2024-03-310000012208bio:KnowHowMember2024-03-310000012208us-gaap:DevelopedTechnologyRightsMember2024-03-310000012208us-gaap:LicensingAgreementsMember2024-03-310000012208us-gaap:TradeNamesMember2024-03-310000012208us-gaap:NoncompeteAgreementsMember2024-03-310000012208us-gaap:InProcessResearchAndDevelopmentMember2024-03-310000012208us-gaap:CustomerRelationshipsMember2023-12-310000012208bio:KnowHowMember2023-12-310000012208us-gaap:DevelopedTechnologyRightsMember2023-12-310000012208us-gaap:LicensingAgreementsMember2023-12-310000012208us-gaap:TradeNamesMember2023-12-310000012208us-gaap:NoncompeteAgreementsMember2023-12-310000012208us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000012208bio:A33SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2024-03-310000012208bio:A33SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2023-12-310000012208bio:A37SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2024-03-310000012208bio:A37SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2023-12-310000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2024-03-310000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2023-12-310000012208us-gaap:LineOfCreditMember2024-02-130000012208us-gaap:LineOfCreditMember2024-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310000012208us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310000012208us-gaap:AllOtherSegmentsMember2024-01-012024-03-310000012208bio:LifeScienceMember2023-01-012023-03-310000012208bio:ClinicalDiagnosticsMember2023-01-012023-03-310000012208us-gaap:AllOtherSegmentsMember2023-01-012023-03-310000012208us-gaap:OperatingSegmentsMember2024-01-012024-03-310000012208us-gaap:OperatingSegmentsMember2023-01-012023-03-310000012208us-gaap:InterestExpenseMemberus-gaap:MaterialReconcilingItemsMember2024-01-012024-03-310000012208us-gaap:InterestExpenseMemberus-gaap:MaterialReconcilingItemsMember2023-01-012023-03-310000012208us-gaap:MaterialReconcilingItemsMember2024-01-012024-03-310000012208us-gaap:MaterialReconcilingItemsMember2023-01-012023-03-310000012208bio:EuropeanReorganizationMember2021-02-012023-09-300000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2023-12-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2023-12-310000012208bio:EuropeanReorganizationMember2023-12-310000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2024-01-012024-03-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2024-01-012024-03-310000012208bio:EuropeanReorganizationMember2024-01-012024-03-310000012208bio:LifeScienceMemberbio:EuropeanReorganizationMember2024-03-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2024-03-310000012208bio:EuropeanReorganizationMember2024-03-310000012208us-gaap:OneTimeTerminationBenefitsMember2024-01-012024-03-310000012208us-gaap:FacilityClosingMember2024-01-012024-03-310000012208bio:EuropeanAndAmericanReorganizationMember2023-02-012023-09-300000012208bio:LifeScienceMemberbio:EuropeanAndAmericanReorganizationMember2023-12-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2023-12-310000012208bio:EuropeanAndAmericanReorganizationMember2023-12-310000012208bio:LifeScienceMemberbio:EuropeanAndAmericanReorganizationMember2024-01-012024-03-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2024-01-012024-03-310000012208bio:EuropeanAndAmericanReorganizationMember2024-01-012024-03-310000012208bio:LifeScienceMemberbio:EuropeanAndAmericanReorganizationMember2024-03-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2024-03-310000012208bio:EuropeanAndAmericanReorganizationMember2024-03-310000012208us-gaap:CostOfSalesMember2024-01-012024-03-310000012208us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000012208us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310000012208srt:MinimumMember2024-01-012024-03-310000012208srt:MaximumMember2024-01-012024-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period endedMarch 31, 2024
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from______________to __________
Commission file number
001-07928
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware94-1381833
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive,Hercules,California94547
(Address of principal executive offices)(Zip Code)
(510)724-7000
(Registrant's telephone number, including area code)
No Change
(Former name, former address and former fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per shareBIONew York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share
BIO.B
New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. YesNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).
YesNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YesNo
.
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Shares Outstanding at May 3, 2024:
Class A - 23,445,692Class B - 5,079,105




BIO-RAD LABORATORIES, INC.

FORM 10-Q MARCH 31, 2024

TABLE OF CONTENTS

2


INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this report include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our future financial performance, operating results, plans and objectives. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, the risks relating to our international operations, supply chain issues, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, reductions in government funding or capital spending of our customers, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under “Part II, Item 1A, Risk Factors” of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
3


PART I – FINANCIAL INFORMATION

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share data)

March 31, 2024December 31, 2023
ASSETS:(Unaudited)
Cash and cash equivalents$433,280 $403,815 
Short-term investments1,212,394 1,203,327 
Restricted investments5,560 5,560 
Accounts receivable, less allowance for credit losses of $15,305 as of March 31, 2024 and $14,926 as of December 31, 2023
444,809 489,017 
Inventory783,369 780,517 
Prepaid expenses142,742 140,040 
Other current assets38,782 26,054 
Total current assets3,060,936 3,048,330 
Property, plant and equipment, net522,364 529,007 
Operating lease right-of-use assets188,918 194,730 
Goodwill, net412,817 413,569 
Purchased intangibles, net313,602 320,514 
Other investments8,018,383 7,698,070 
Other assets92,873 94,850 
Total assets$12,609,893 $12,299,070 
























The accompanying notes are an integral part of these condensed consolidated financial statements.
4






BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(continued)
(In thousands, except share data)

March 31, 2024December 31, 2023
LIABILITIES AND STOCKHOLDERS’ EQUITY:(Unaudited) 
Accounts payable$102,750 $144,625 
Accrued payroll and employee benefits146,491 139,929 
Current maturities of long-term debt and notes payable487 486 
Income and other taxes payable33,961 35,759 
Current operating lease liabilities40,038 40,379 
Other current liabilities142,427 161,621 
Total current liabilities466,154 522,799 
Long-term debt, net of current maturities1,199,381 1,199,052 
Deferred income taxes1,540,992 1,475,495 
Operating lease liabilities159,814 165,478 
Other long-term liabilities192,418 195,113 
Total liabilities3,558,759 3,557,937 
Stockholders’ equity:  
Class A common stock, shares issued 25,186,769 and 25,169,944 as of March 31, 2024 and December 31, 2023, respectively; shares outstanding 23,444,836 and 23,422,506 as of March 31, 2024 and December 31, 2023, respectively
2 2 
Class B common stock, shares issued and outstanding, 5,079,105 as of March 31, 2024 and 5,095,930 as of December 31, 2023, respectively
1 1 
Additional paid-in capital462,627 449,075 
Class A treasury stock at cost, 1,741,933 and 1,747,438 shares as of March 31, 2024 and December 31, 2023, respectively
(630,070)(632,536)
Retained earnings9,644,545 9,260,629 
Accumulated other comprehensive loss
(425,971)(336,038)
Total stockholders’ equity9,051,134 8,741,133 
Total liabilities and stockholders’ equity$12,609,893 $12,299,070 













The accompanying notes are an integral part of these condensed consolidated financial statements. 
5




BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)
 Three Months Ended
 March 31,
 20242023
Net sales$610,820 $676,844 
Cost of goods sold284,854 314,427 
Gross profit325,966 362,417 
Selling, general and administrative expense214,883 225,553 
Research and development expense66,375 74,951 
Income from operations44,708 61,913 
Interest expense12,277 12,337 
Foreign currency exchange gains, net(1,954)(2,347)
(Gains) losses from change in fair market value of equity securities and loan receivable(422,177)17,525 
Other income, net(34,516)(50,431)
Income before income taxes491,078 84,829 
Provision for income taxes(107,162)(15,867)
Net income$383,916 $68,962 
Basic earnings per share:
  
Net income per basic share
$13.46 $2.33 
Weighted average common shares - basic28,518 29,596 
Diluted earnings per share:  
Net income per diluted share$13.45 $2.32 
Weighted average common shares - diluted28,537 29,747 















The accompanying notes are an integral part of these condensed consolidated financial statements. 
6


BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Comprehensive Income
(In thousands)
(Unaudited)
Three Months Ended
March 31,
 20242023
Net income
$383,916 $68,962 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments(91,668)55,219 
Foreign other post-employment benefits adjustments1,354 33 
Net unrealized holding gains on available-for-sale (AFS) investments381 3,218 
Other comprehensive income (loss)(89,933)58,470 
Comprehensive income$293,983 $127,432 



The accompanying notes are an integral part of these condensed consolidated financial statements.

7


BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
 Three Months Ended
 March 31,
 20242023
Cash flows from operating activities:  
Cash received from customers$638,324 $677,522 
Cash paid to suppliers and employees(560,316)(552,990)
Interest paid, net(22,425)(22,482)
Income tax payments, net(3,835)(13,283)
Dividend proceeds and miscellaneous receipts, net
15,835 14,662 
Proceeds from (payments for) forward foreign exchange contracts, net2,209 (5,310)
Net cash provided by operating activities69,792 98,119 
Cash flows from investing activities:  
Payments for purchases of property, plant and equipment(40,176)(35,725)
Proceeds from dispositions of property, plant and equipment26  
Payments for purchases of marketable securities and investments(406,458)(203,588)
Proceeds from sales of marketable securities and investments331,463 92,751 
Proceeds from maturities of marketable securities and investments72,052 76,089 
Net cash used in investing activities(43,093)(70,473)
Cash flows from financing activities:  
Payments on long-term borrowings(118)(115)
Payments for debt issuance costs
(617) 
Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options5,505 4,424 
Payments for purchases of treasury stock(4,749) 
Net cash provided by financing activities21 4,309 
Effect of foreign exchange rate changes on cash2,663 (1,996)
Net increase in cash, cash equivalents and restricted cash29,383 29,959 
Cash, cash equivalents and restricted cash at beginning of period404,369 434,544 
Cash, cash equivalents and restricted cash at end of period$433,752 $464,503 

Reconciliation of cash, cash equivalents and restricted cash (in thousands):
March 31,
20242023
Cash and cash equivalents$433,280 $464,136 
Restricted cash included in Other current assets51 47 
Restricted cash included in Other assets421 320 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$433,752 $464,503 

These restricted cash items are primarily related to performance guarantees and other restricted deposits.

The accompanying notes are an integral part of these condensed consolidated financial statements.

8




BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(In thousands)
(Unaudited)
Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
Balance at December 31, 2023$3 $449,075 $(632,536)$9,260,629 $(336,038)$8,741,133 
Net income   383,916  383,916 
Other comprehensive loss, net of tax    (89,933)(89,933)
Stock compensation expense 15,262    15,262 
Purchase of treasury stock  (4,702)  (4,702)
Reissuance of treasury stock (1,710)7,215   5,505 
Excise tax on stock repurchase
  (47)  (47)
Balance at March 31, 2024$3 $462,627 $(630,070)$9,644,545 $(425,971)$9,051,134 


Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
Balance at December 31, 2022$3 $447,454 $(263,586)$9,898,203 $(466,822)$9,615,252 
Net income   68,962  68,962 
Other comprehensive income, net of tax    58,470 58,470 
Stock compensation expense 16,608    16,608 
Reissuance of treasury stock— (660)5,290 (206)— 4,424 
Balance at March 31, 2023$3 $463,402 $(258,296)$9,966,959 $(408,352)$9,763,716 

























The accompanying notes are an integral part of these condensed consolidated financial statements. 
9


BIO-RAD LABORATORIES, INC

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.

Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is
10


allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.

We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.

We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.

Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three months ended March 31, 2024 and March 31, 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income.


11


Contract costs:

We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income.

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region (in millions):
Three Months Ended
March 31,
20242023
United States$252.9 $297.0 
EMEA200.2 204.8 
APAC117.2 135.8 
Other (primarily Canada and Latin America)40.5 39.2 
Total net sales$610.8 $676.8 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).

Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at March 31, 2024 and December 31, 2023 was $70.8 million and $68.3 million, respectively. The short-term deferred revenue balance at March 31, 2024 and December 31, 2023 was $55.1 million and $51.1 million, respectively.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income.

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three months ended March 31, 2024 and 2023 were as follows (in millions):
Three Months Ended
March 31,
20242023
Balance at beginning of period$8.4 $10.6 
Provision for warranty1.4 2.0 
Actual warranty costs(2.3)(2.7)
Balance at end of period$7.5 $9.9 

Accounts Receivable and Allowance for Credit Losses
We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.

12


Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.

Changes in our allowance for credit losses were as follows (in millions):
Three Months Ended
March 31,
20242023
Balance at beginning of period$14.9 $15.0 
Provision for expected credit losses1.6 0.6 
Write-offs charged against the allowance(1.2)(0.4)
Balance at end of period$15.3 $15.2 

Recent Accounting Pronouncements Issued and to be Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, “Improvements to Reportable Segment Disclosures.” The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker (CODM). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.

In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. We are currently evaluating the final rule to determine its impact on our disclosures.


2. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

Level 1: Quoted prices in active markets for identical instruments
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

13


Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2024 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Time deposits 50.0  50.0 
Money market funds137.4   137.4 
Total cash equivalents (a)137.4 50.0  187.4 
Restricted investments (b)7.1   7.1 
Equity securities (c)7,721.7   7,721.7 
Loan under the fair value option (d)  330.6 330.6 
Available-for-sale investments:
Corporate debt securities 551.0  551.0 
U.S. government sponsored agencies 281.4  281.4 
Foreign government obligations 3.8  3.8 
Municipal obligations 9.5  9.5 
Asset-backed securities 293.3  293.3 
Total available-for-sale investments (e) 1,139.0  1,139.0 
Forward foreign exchange contracts (f) 2.3  2.3 
Total financial assets carried at fair value$7,866.2 $1,191.3 $330.6 $9,388.1 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$ $1.3 $ $1.3 
Contingent consideration (h)  17.7 17.7 
Total financial liabilities carried at fair value$ $1.3 $17.7 $19.0 


14


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$ $12.5 $ $12.5 
Time deposits 36.6  36.6 
U.S. government sponsored agencies 7.0  7.0 
Money market funds28.0   28.0 
Total cash equivalents (a)28.0 56.1  84.1 
Restricted investments (b)7.1   7.1 
Equity securities (c)7,399.3   7,399.3 
Loan under the fair value option (d)  325.7 325.7 
Available-for-sale investments:
Corporate debt securities 531.6  531.6 
U.S. government sponsored agencies 255.9  255.9 
Foreign government obligations 12.7  12.7 
Municipal obligations 12.1  12.1 
Asset-backed securities 323.7  323.7 
Total available-for-sale investments (e) 1,136.0  1,136.0 
Forward foreign exchange contracts (f) 4.1  4.1 
Total financial assets carried at fair value$7,434.4 $1,196.2 $325.7 $8,956.3 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$ $11.7 $ $11.7 
Contingent consideration (h)  17.5 17.5 
Total financial liabilities carried at fair value$ $11.7 $17.5 $29.2 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2024December 31, 2023
Restricted investments$5.6 $5.6 
Other investments1.5 1.5 
    Total$7.1 $7.1 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2024December 31, 2023
Short-term investments$73.3 $67.2 
Other investments7,648.4 7,332.1 
        Total$7,721.7 $7,399.3 

(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.
15



(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.2 million in the consolidated statements of income for the three months ended March 31, 2024. No conditions triggering payment of the contingent consideration were met as of March 31, 2024.

Level 1 Fair Value Measurements

As of March 31, 2024, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the outstanding ordinary shares (excluding treasury shares) and 27% of the preference shares of Sartorius as of March 31, 2024. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.

The change in fair market value of our investment in Sartorius for the three months ended March 31, 2024 was a gain of $402.3 million, and is recorded in our condensed consolidated statements of income.

Level 2 Fair Value Measurements

To estimate the fair value of Level 2 debt securities as of March 31, 2024 and December 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

Available-for-sale investments consist of the following (in millions):
 March 31, 2024
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$553.3 $0.8 $(3.1)$551.0 
Municipal obligations9.6  (0.1)9.5 
Asset-backed securities294.4 0.6 (1.7)293.3 
U.S. government sponsored agencies283.5 0.1 (2.2)281.4 
Foreign government obligations3.8   3.8 
 $1,144.6 $1.5 $(7.1)$1,139.0 

The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2024 by contractual maturity date (in millions):
16


Amortized
Cost
Estimated Fair
Value
Mature in less than one year$272.1 $270.3 
Mature in one to five years724.7 721.7 
Mature in more than five years147.8 147.0 
Total$1,144.6 $1,139.0 

Available-for-sale investments consist of the following (in millions):
 December 31, 2023
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$534.1 $0.8 $(3.3)$531.6 
Municipal obligations12.2  (0.1)12.1 
Asset-backed securities325.7 0.7 (2.7)323.7 
U.S. government sponsored agencies257.4 0.1 (1.6)255.9 
Foreign government obligations12.8  (0.1)12.7 
Total$1,142.2 $1.6 $(7.8)$1,136.0 

As of March 31, 2024, there were no significant continuous unrealized losses greater than 12 months.

Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At March 31, 2024, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2024.
Included in Other current assets are $14.8 million and $11.9 million of interest receivable as of March 31, 2024 and December 31, 2023, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2024, we have not written-off any uncollected interest receivable.

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of March 31, 2024 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the
17


related receivables and payables, both of which are included in Foreign currency exchange gains, net in the condensed consolidated statements of income.

The following is a summary of our forward foreign currency exchange contracts (in millions):

Contracts maturing in April through June 2024 to sell foreign currency:
March 31, 2024
Notional value$673.7 
Unrealized loss$0.8 
Contracts maturing in April through June 2024 to purchase foreign currency:
 
Notional value$65.1 
Unrealized gain$0.1 

Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $6.5 million as of March 31, 2024 and December 31, 2023.

Also included in Other investments in the condensed consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in Other income, net in our condensed consolidated statements of income. The carrying value of these investments, net of impairments, was $31.3 million and $32.3 million as of March 31, 2024 and December 31, 2023, respectively.

The carrying value and fair value of our long-term debt were as follows (in millions):

March 31, 2024December 31, 2023
Carrying Value
Fair Value
Carrying ValueFair Value
Senior notes
$1,189.9 $1,097.2 $1,189.5 $1,102.5 
Other long-term debt
9.5 9.5 9.6 9.6 
Total
$1,199.4 $1,106.7 $1,199.1 $1,112.1 

The fair value of our long-term debt was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.

Level 3 Fair Value Investments

During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (“Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and
18


value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended March 31, 2024 was a gain of $12.3 million, which includes a $8.8 million gain from change in fair market value of the Loan and a $3.5 million gain from change in fair market value of the value appreciation right. The increase in the fair market value of the value appreciation right was due to an increase in the value of the Sartorius ordinary shares. As of March 31, 2024, the €400 million principal amount of the loan is still due on January 31, 2029.

The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2023$325.7 
Net increase in estimated fair market value of the loan included in Gains (losses) in fair market value of equity securities and loan receivable
$12.3 
Foreign currency exchange gains (losses), net$(7.4)
March 31, 2024$330.6 

19



3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment are as follows (in millions):
Life
Science
Clinical
Diagnostics
Total
Balances as of January 1, 2024:
Goodwill$333.3 $415.5 $748.8 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net291.5 122.1 413.6 
Foreign currency adjustments (0.8)(0.8)
Period increase, net (0.8)(0.8)
Balances as of March 31, 2024:
Goodwill333.3 414.7 748.0 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$291.5 $121.3 $412.8 

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):
March 31, 2024
Weighted-Average Remaining Amortization Period (years)Purchase
Price
Accumulated
Amortization
Net
Carrying
Amount
Customer relationships/lists5.1$105.7 $(96.8)$8.9 
Know how1.5166.9 (160.2)6.7 
Developed product technology11.9216.9 (134.5)82.4 
Licenses4.759.0 (43.1)15.9 
Tradenames5.36.0 (4.6)1.4 
Covenants not to compete2.06.5 (5.1)1.4 
     Total finite-lived intangible assets561.0 (444.3)116.7 
In-process research and development196.9 — 196.9 
     Total purchased intangible assets $757.9 $(444.3)$313.6 

20


 December 31, 2023
Weighted-Average Remaining Amortization Period (years)Purchase
Price
Accumulated
Amortization
Net
Carrying
Amount
Customer relationships/lists5.2$108.7 $(98.9)$9.8 
Know how1.8168.9 (161.1)7.8 
Developed product technology12.0217.8 (132.9)84.9 
Licenses4.959.2 (42.4)16.8 
Tradenames5.66.1 (4.7)1.4 
Covenants not to compete2.36.4 (4.8)1.6 
     Total finite-lived intangible assets567.1 (444.8)122.3 
In-process research and development198.2 — 198.2 
     Total purchased intangible assets $765.3 $(444.8)$320.5 

Amortization expense related to purchased intangible assets is as follows (in millions):

Three Months Ended
 March 31,
 20242023
Amortization expense$5.5 $6.0 



4. INVENTORY

Following are the components of Inventory at March 31, 2024 and December 31, 2023 (in millions):

March 31, 2024December 31, 2023
Inventory:
  Raw materials$226.1 $231.6 
  Work in process250.4 246.0 
  Finished goods 306.9 302.9 
      Total Inventory$783.4 $780.5 

21



5. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net income to net cash provided by operating activities is as follows (in millions):
Three Months Ended
March 31,
20242023
Net income$383.9 $69.0 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization37.1 35.6 
Reduction in the carrying amount of right-of-use assets10.7 10.0 
Share-based compensation15.3 16.6 
(Gains) losses from change in fair market value of equity securities and loan receivable(422.2)17.5 
Payments for operating lease liabilities(10.9)(9.9)
(Increase) decrease in accounts receivable37.4 (1.4)
Increase in inventories(8.8)(30.1)
Increase in other current assets(26.3)(16.0)
Increase (decrease) in accounts payable and other current liabilities(44.4)8.2 
Increase in income taxes payable12.3 10.4 
Increase (decrease) in deferred income taxes84.2 (13.9)
Increase (decrease) in other long-term liabilities(0.4)2.5 
Other1.9 (0.4)
Net cash provided by operating activities$69.8 $98.1 
Non-cash investing activities:
Purchased property, plant and equipment$3.5 $8.4 
Purchased marketable securities and investments$2.3 $6.3 

22



6. LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):
March 31,
2024
December 31,
2023
3.3%, Senior Notes due 2027
$400.0 $400.0 
3.7%, Senior Notes due 2032
800.0 800.0 
Less unamortized discounts and debt issuance costs(10.1)(10.5)
Long-term debt less unamortized discounts and debt issuance costs1,189.9 1,189.5 
Finance leases and other debt10.0 10.1 
Less current maturities(0.5)(0.5)
Long-term debt$1,199.4 $1,199.1 

On February 13, 2024, we entered into a new $200.0 million unsecured revolving credit agreement ("Revolving Credit Agreement") with a group of financial institutions. The Revolving Credit Agreement replaced the Company's previous credit agreement, dated as of April 15, 2019. Borrowings under the Revolving Credit Agreement are on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. The Revolving Credit Agreement requires Bio-Rad to comply with certain financial ratios and other customary covenants and provisions. The Revolving Credit Agreement matures on February 13, 2029. As of March 31, 2024, no borrowings were outstanding under the Revolving Credit Agreement, although available capacity was reduced by immaterial outstanding letters of credit. We were in compliance with the covenants for the Revolving Credit Agreement during the three months ended March 31, 2024.


7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2024:$(334.1)$(2.8)$0.9 $(336.0)
Other comprehensive income (loss), before reclassifications(92.1)0.3 0.3 (91.5)
Amounts reclassified from Accumulated other comprehensive income (loss) (0.1)0.2 0.1 
Income tax effects0.3 1.2 (0.1)1.4 
Other comprehensive income (loss), net of income taxes(91.8)1.4 0.4 (90.0)
Balances as of March 31, 2024:$(425.9)$(1.4)$1.3 $(426.0)
23


Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2023:$(466.5)$10.0 $(10.3)$(466.8)
Other comprehensive income, before reclassifications55.4 0.1 4.0 59.5 
Amounts reclassified from Accumulated other comprehensive income (loss) (0.1)0.2 0.1 
Income tax effects(0.2)0.1 (1.0)(1.1)
Other comprehensive income, net of income taxes55.2 0.1 3.2 58.5 
Balances as of March 31, 2023:$(411.3)$10.1 $(7.1)$(408.3)

All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income. The reclassification adjustments are calculated using the specific identification method.

The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive
income (loss) into other income, net in the condensed consolidated statements of income were as follows (in
millions):
Three Months Ended
March 31,
Components of comprehensive income (loss)20242023
Amortization of foreign other post-employment benefit items$(0.1)$(0.1)
Net holding gains on equity securities and available-for-sale investments
$0.2 $0.2 


8. EARNINGS PER SHARE

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.

We compute net income per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the three months ended March 31, 2024 and 2023.

24


Accordingly, basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands):
Three Months Ended
March 31,
 20242023
Basic weighted average shares outstanding28,518 29,596 
Effect of potentially dilutive stock options, restricted stock and performance stock awards19 151 
Diluted weighted average common shares outstanding28,537 29,747 
Anti-dilutive shares351 94 


9. OTHER INCOME, NET

Other income, net includes the following components (in millions):
Three Months Ended
March 31,
 20242023
Interest and investment income$(34.0)$(50.3)
Net realized losses on investments0.2 0.7 
Other income(0.7)(0.8)
Other income, net$(34.5)$(50.4)



10. INCOME TAXES

Our effective income tax rate was 21.8% and 18.7% for the three months ended March 31, 2024 and 2023, respectively.

The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of March 31, 2024, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets decreased by $1.3 million for the period ended March 31, 2024 compared to the year ended December 31, 2023.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are
25


differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our gross unrecognized tax benefits were $86.1 million and $84.7 million as of March 31, 2024 and December 31, 2023, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.

As of March 31, 2024, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $17.2 million. Substantially all such amounts will impact our effective income tax rate if recognized.

11. SEGMENT INFORMATION

Information regarding net sales and operating profit (loss) for the three months ended March 31, 2024 and 2023 are as follows (in millions):

Life
Science
Clinical
Diagnostics
Other
Operations
Net sales2024$241.7 $368.6 $0.5 
 2023$323.6 $352.1 $1.1 
Operating profit (loss)2024$(8.2)$53.1 $(0.2)
 2023$35.7 $26.3 $(0.1)

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.

The following reconciles total operating profit to consolidated income before income taxes (in millions):

Three Months Ended
March 31,
 20242023
Operating profit$44.7 $61.9 
Interest expense(12.3)(12.3)
Foreign currency exchange gains, net
2.0 2.3 
Gains (losses) from change in fair market value of equity securities and loan receivable
422.2 (17.5)
Other income, net34.5 50.4 
Consolidated income before income taxes
$491.1 $84.8 

26



12. LEGAL PROCEEDINGS

We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


13. RESTRUCTURING COSTS

In February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of March 31, 2024. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to March 31, 2024, total restructuring-related expenses were $71.8 million.

The following table summarizes the activity of our February 2021 plan accrued restructuring reserve (in millions):
Life ScienceClinical DiagnosticsTotal
Balances as of January 1, 2024:$0.2 $12.8 $13.0 
Adjustment to expense0.1 1.0 1.1 
Cash payments (3.2)(3.2)
Foreign currency adjustments (0.3)(0.3)
Balances as of March 31, 2024:$0.3 $10.3 $10.6 

During the fiscal year ended December 31, 2023, and continuing into the quarter ended March 31, 2024, management approved a restructuring action to further streamline and improve operating performance. The restructuring plan was approved and implemented in phases. The plan is expected to be substantially completed by the end of 2024.

During the three months ended March 31, 2024, a new phase of the restructuring plan was approved resulting in restructuring expenses of $5.3 million, representing estimated termination benefits to employees. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits on previously approved phases. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. Excluded from the accrued restructuring plan reserves are $1.6 million of restructuring expense related to the facility closure costs impacting the Life Science segment. From February 2023 to March 31, 2024, total restructuring-related expenses were $31.8 million, primarily representing estimated termination benefits to employees.

The following table summarizes the activity of our 2023 accrued restructuring plan reserve (in millions):

27


Life ScienceClinical DiagnosticsTotal
Balances as of January 1, 2024:$3.0 $7.8 $10.8 
Charged to expense - employee termination benefits
2.1 3.2 5.3 
Adjustment to expense
(0.3)(0.6)(0.9)
Cash payments(2.4)(4.6)(7.0)
Foreign currency adjustments (0.2)(0.2)
Balances as of March 31, 2024:$2.4 $5.6 $8.0 


Combined, the accrued restructuring plan reserve of $18.7 million as of March 31, 2024 was recorded in Accrued payroll and employee benefits in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended March 31, 2024 were $0.5 million, $4.4 million and $2.2 million, respectively, in the condensed consolidated statements of income.


14. LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 15 years, which includes our determination to exercise renewal options.

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

The components of lease expense were as follows (in millions):
Three Months Ended
March 31,
20242023
Operating lease cost$18.1 $15.8 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 
  Interest on lease liabilities0.2 0.2 
        Total finance lease cost$0.3 $0.3 

28


Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.

Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three months ended March 31, 2024 and 2023. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three months ended March 31, 2024 and 2023.

Supplemental cash flow information related to leases was as follows (in millions):
Three Months Ended
March 31,
20242023
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$10.9 $9.9 
  Operating cash flows from finance leases$0.2 $0.2 
  Financing cash flows from finance leases$0.1 $0.1 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$7.6 $2.2 

Supplemental balance sheet information related to leases was as follows (in millions):
March 31, 2024December 31, 2023
Operating Leases
  Operating lease right-of-use assets$188.9 $194.7 
  Current operating lease liabilities$40.0 $40.4 
  Operating lease liabilities159.8 165.5 
     Total operating lease liabilities$199.8 $